New Zealand firm Medleaf and Northern Green Canada (NGC) have completed their first shipment of non-irradiated EU/GMP-certified medicinal cannabis flower into NZ.
Medleaf has partnered with NGC for the initial supply of a medium THC flower product, which is currently under assessment by the NZ Medical Cannabis Agency to ensure it meets the country’s quality standards.
Medleaf director Courtney Letica said: “Our ultimate aim is to develop New Zealand’s most recognised brand, with leading partners offering our patients the best products and prices available globally.”
“NGC’s expertise in the Canadian market and in delivering GMP flower makes [it] a perfect partner to satisfy the demands of New Zealand patients [with] an exciting pipeline of products in development.”
President of NGC Lisa McCormack added: “This successful shipment represents a major milestone for our company. Following our recent EU/GMP certification, our expansion into international markets like New Zealand makes it possible for us to reach patients globally.”